{"id":2104,"name":"Astellas Venture Management","slug":"astellas-venture-management","website":"https://www.astellasventure.com","hqGeo":"Menlo Park, CA","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Other","Healthcare","AI / ML"],"excludedSectors":[],"checkSizeMin":1500000,"checkSizeMax":10000000,"thesisSummary":"Astellas Venture Management invests in early-stage therapeutic innovation, focusing on biopharma and AI-based drug design.","thesisNarrative":null,"logoUrl":null,"aumUsd":67500000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"Atomwise","companyUrl":null,"stage":null,"sector":"AI Drug Discovery","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Vector BioPharma","companyUrl":null,"stage":null,"sector":"Biotech","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"DeepSeq.AI","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Serna Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Solu Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops therapeutics targeting soluble targets in immunology and inflammation.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"PhoreMost","companyUrl":null,"stage":"Series B - II","sector":"Oncology (immuno-oncology)","investmentYear":null,"description":"UK-based developer of small molecule neoantigen immuno-oncology therapies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Somite Therapeutics","companyUrl":null,"stage":"Pre-Seed - II","sector":"Regenerative medicine (muscle)","investmentYear":null,"description":"Builds cellular therapies for muscle diseases using stem cell tech.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Turn Biotechnologies","companyUrl":null,"stage":null,"sector":"Health/Medical (regenerative)","investmentYear":null,"description":"Develops mRNA-based therapies for cellular rejuvenation in age-related diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"CoMentis","companyUrl":null,"stage":null,"sector":"Biotechnology (neuro)","investmentYear":null,"description":"Focuses on neurodegenerative disease therapies targeting protein misfolding.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Avilar Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology (degradation)","investmentYear":null,"description":"Engineers protein degradation platforms for autoimmune and inflammatory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Casma Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology (autophagy)","investmentYear":null,"description":"Advances autophagy-based therapies for neurodegeneration and metabolic diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Catamaran Bio","companyUrl":null,"stage":null,"sector":"Oncology (immunotherapy)","investmentYear":null,"description":"Develops allogeneic CAR-NK therapies for cancer.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cleave Biosciences","companyUrl":null,"stage":null,"sector":"Biotechnology (degradation)","investmentYear":null,"description":"Targets protein degradation for cancer and immune diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"CODA Biotherapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology (neuro, antibodies)","investmentYear":null,"description":"Engineers multispecific antibodies for neurological disorders.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Heartseed","companyUrl":null,"stage":"exited","sector":"Regenerative (cardiology)","investmentYear":null,"description":"Cardiac regenerative therapies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Potenza Therapeutics","companyUrl":null,"stage":"Acq - Fin","sector":"Oncology","investmentYear":null,"description":"Immunotherapy platforms.","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":5,"partners":[{"id":10415,"name":"Shinichi Miyake, Ph.D., MBA","title":"Investment Lead","seniority":null,"focusTags":["Small Molecules","Cell Therapy","Gene Therapy","Modality-based Drug Discovery"],"linkedinUrl":"https://www.linkedin.com/in/shinichi-miyake","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":21335,"name":"William Watt, Ph.D.","title":"President","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/william-watt-phd-1b1a1a8","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":10413,"name":"Tadayoshi Hirata","title":"Investment Lead","seniority":null,"focusTags":["Early-stage partnering deals","Translational science","Clinical pharmacology"],"linkedinUrl":"https://www.linkedin.com/in/tadayoshi-hirata","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":10414,"name":"Nagisa Sakurai, Ph.D., MBA","title":"Investment Lead","seniority":null,"focusTags":["Regenerative Medicine","Cardiovascular”, “Ophthalmology","Stem Cell Therapy"],"linkedinUrl":"https://www.linkedin.com/in/nagisa-sakurai","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":10412,"name":"Satoshi Konagai, MBA","title":"Investment Lead","seniority":null,"focusTags":["Oncology","Ophthalmology","Regenerative Medicine"],"linkedinUrl":"https://www.linkedin.com/in/satoshi-konagai-7a4781a2","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsLast12Months":0},"investorType":"vc","preferredApproach":"cold outreach ok","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":13023,"name":"Volition Capital Fund","slug":"volition-capital-fund","logoUrl":null,"website":"https://www.volitioncapital.com/","stageFocus":["Pre-Seed"],"sectorTags":["SaaS","AI / ML","Developer Tools","Other","Security"],"hqGeo":"Boston, MA"},{"id":7722,"name":"Sheesha Finance","slug":"sheesha-finance","logoUrl":null,"website":"https://sheeshafinance.gitbook.io/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Fintech"],"hqGeo":null},{"id":13762,"name":"NeuroNet Ventures","slug":"neuronet-ventures","logoUrl":null,"website":"https://neuronetgpo.com/","stageFocus":["Seed"],"sectorTags":["AI / ML","Other"],"hqGeo":"Chicago, IL"},{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Other","Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"},{"id":10388,"name":"Africa Tech Ventures","slug":"africa-tech-ventures","logoUrl":null,"website":null,"stageFocus":["Pre-Seed","Seed"],"sectorTags":["Other","AI / ML","Food / AgTech","Consumer","Fintech","EdTech"],"hqGeo":"Nairobi, Kenya"},{"id":10277,"name":"Structural Capital Ventures","slug":"structural-capital-ventures","logoUrl":null,"website":"https://structuralcapital.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["AI / ML","Other","Developer Tools","SaaS"],"hqGeo":"Austin, TX"}],"featuredIn":[{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"ai","displayName":"AI & ML Investors","pageType":"industry"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"Finding-Investors-For-Startup-In-2026","title":"How to Find Investors for Your Startup in 2026 (Without Cold-Searching Databases)"},{"slug":"how-vcs-help-portfolio-raise-follow-on","title":"How VCs Can Actually Help Their Portfolio Companies Raise Follow-On"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-05-04T00:16:06.544Z"}